Hypoparathyroidism

Adults with inadequately controlled hypoparathyroidism reported substantial symptoms related to the disease and health-related quality of life, with the effect compared with other severe, chronic diseases, according to findings published in Clinical Endocrinology.

Aerami Therapeutics, formerly Dance Biopharm, announced this week it is rebranding and expanding its pipeline to include several inhaled endocrine therapies, according to a company press release.

Takeda recently announced it is issuing a U.S. recall for all doses of its parathyroid hormone injection due to potential rubber particulate contamination originating from the rubber septum of the product’s cartridge, according to a statement released by the FDA.

Adults with chronic hypoparathyroidism treated with recombinant human parathyroid hormone 1-84 for 5 years experienced sustained improvements in mineral homeostasis and modest increases in bone turnover markers, whereas serum calcium remained in the target range with reductions in oral calcium supplements, according to findings from a small, open-label extension study.